In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Best Laid Plans: Pfizer's Torcetrapib Tanks

Executive Summary

Pfizer's decision to discontinue the development of it's Phase III high-density lipoprotein-boosting torcetrapib in early December leaves the Big Pharma with little choice but to accelerate its restructuring plans and start spending some of its estimated $34 billion cash reserves to bolster its pipeline.

Related Content

Future Appears Grim For Pfizer's Tanezumab With Ostearthritis Trial Stopped
Can Out-Partnering Help Vault Pfizer Over the "Second Cliff"?
Esperion, Again: Pfizer's First Spin-Out's Familiar Look
Exubera's Problem: It's Still Just Insulin
Pfizer Deal Highlights Bristol's Biotech Swagger
Reliant: The Expensive Opportunities in Primary Care
Pfizer's Change Management: Unfamiliar Faces
Pfizer's Change Management: Unfamiliar Faces
Pfizer's Analyst Day: And Now, For Its Next Trick
Pfizer's Analyst Day: And Now, For Its Next Trick


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts